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Abstract: 
In randomized clinical trials with survival outcome, there has been an increasing interest in 
subgroup identification based on baseline genomic, proteomic markers or clinical characteristics. 
Some of the existing methods identify subgroups that benefit substantially from the experimental 
treatment by directly modeling outcomes or treatment effect. When the goal is to find an optimal 
treatment for a given patient rather than finding the right patient for a given treatment, methods 
under the individualized treatment regime framework estimate an individualized treatment rule 
that would lead to the best expected clinical outcome as measured by a value function. 
Connecting the concept of value function to subgroup identification, we propose a nonparametric 
method that searches for subgroup membership scores by maximizing a value function that 
directly reflects the subgroup-treatment interaction effect based on restricted mean survival time. 
A gradient tree boosting algorithm is proposed to search for the individual subgroup membership 
scores. We conduct simulation studies to evaluate the performance of the proposed method and 
an application to an AIDS clinical trial is performed for illustration. 
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1 Introduction 
Although randomized clinical trials can establish the overall comparative treatment effect in a 
target patient population, patients may have heterogenous responses to treatments in reality. For 
example, a drug not benefiting the whole population may work for a subgroup. 1 An important 
goal of personalized medicine is to characterize treatment effect heterogeneity and to identify 
patient subgroups that exhibit differential treatment effects. The relevant statistical research can 
be commonly categorized into two frameworks: the first framework aims at identifying the right 
patient for a given treatment, often loosely grouped together as the subgroup identification 
methods; the second framework deals with identifying the right treatment for a given patient, 2 
commonly referred as individualized treatment regime (ITR) in the literature.  
For both randomized clinical trials and observational studies, an intuitive approach to 
identify patients who would have different clinical outcome under one treatment versus the other 
is to model the potential outcomes under either treatment. 3 Many methods followed this general 
concept to model the outcome conditional on patient characteristics and biomarkers. 4–14 Notably, 
machine learning methods have been proposed to achieve flexible and accurate prediction of 
clinical outcomes in this context (e.g. the Virtual Twin approach, 9 Counterfactual and Bivariate 
Random Forest, 13 and most recently a Gradient Boosting Tree-based approach14 which is built 
on proportional hazard model for censored survival data). Since the outcomes can be affected by 
both main effects of baseline biomarkers and biomarker-treatment interactions in a very complex 
way, the performance of outcome modeling methods could be hurt by the model 
misspecification. In addition, the optimization criteria for predictive outcome modeling may not 
necessary align with the objective of identifying differential treatment effects. That is, what 
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constitutes as the best predictive model for the clinical outcomes does not guarantee to optimize 
a reasonable value function for the subgroup identification or individual treatment 
recommendation problem.  
An alternative strategy is to model the between-group treatment effect in the entire covariate 
space or in subsets of covariate space with enhanced treatment effect. 15–22 The treatment effect 
modeling methods bypass the estimation of main effects and is more robust to model 
misspecification, but similarly the final identified subgroups do not connect with an overall 
expected clinical benefit that arguably should be maximized.  
Under the ITR framework, Qian and Murphy23 introduced the notion of value function which 
reflects an expected clinical outcome for a treatment regime. The focus is to estimate the optimal 
treatment regime, if followed by all patients, would maximize the value function (assuming 
larger value represents better clinical benefit). Zhao et al.24 ang Zhang et al.25 transformed the 
value function optimization to a weighted classification problem known as outcome weighted 
learning. Numerous methods have been proposed under this framework, 26–38 with developments 
in the areas of robust estimation, variable selection, and sparse or interpretable treatment regime 
using tree-based methods. Among the clinical endpoints considered by ITR methods, the time-to-
event or survival endpoints deserve some special attention. The ITR methods by construct utilize 
the individual survival outcome without the context of any specific candidate subgroups. 
Therefore, a censored survival outcome is either treated the same way as an observed event of 
the same duration in the outcome weighted learning approach, 31 or the explicit modeling of the 
censoring probability must be carried out in conjunction. 32 Neither approach is ideal. The first 
approach ignores the different information implied in a censored survival outcome, while the 
second approach involves additional modeling that is susceptible to model misspecification. In 
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traditional survival analysis, censoring information under the assumption of noninformative 
censoring is interpreted in a population context, contributing to the number at risk at an event 
time point without any explicit modeling. Such interpretation extends naturally in the subgroup 
identification framework, where the censored survival data together with observed events define 
the survival distribution in a candidate subgroup. 
While conventionally the survival data comparison in clinical trials are often based on log-
rank test and cox proportional hazard model, restricted mean survival time (RMST) has received 
increasing attentions thanks to its intuitive interpretation, especially in the presence of non-
proportional hazards. 39-41 For the subgroup identification problem in randomized clinical trials, 
the difference of RMST between two treatment groups under consideration has its unique appeal 
as the measure of treatment benefit. It is a model-free quantity that reflects the clinical intuition 
that wider space between two survival curves represents more survival benefit. In addition, the 
product of subgroup prevalence and the difference in RMST approximate a “total” measure of 
survival benefit from a public health perspective (the “mean” multiplied by the number of 
subjects). Furthermore, censoring information is accounted for naturally in the calculation of 
RMST. 
    In practice, it is of great interest to evaluate the effect of subgroup identification. Xu31 
proposed two quantities in which one measures the average experimental treatment effect in 
subgroup that experimental treatment leads to better clinical outcome (treatment performing 
subgroup) and the other quantity measures average control effect in subgroup that experimental 
treatment not leads to better outcome (treatment non-performing subgroup). An ideal subgroup 
identification would maximize both quantities. We extend Xu’s idea by combining the two 
quantities together as a measure of the subgroup identification. Specifically, the new measure is 
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defined as the experimental treatment effect in treatment performing subgroup weighted by the 
treatment performing subgroup prevalence minus the experimental treatment effect in treatment 
non-performing subgroup weighted by the treatment non-performing subgroup prevalence. The 
new quantity reflects a measure of subgroup-treatment interaction effect and an ideal subgroup 
identification would maximize it. For censored survival data, the experimental treatment effect 
can be estimated by the difference in RMST between the experimental treatment group and 
control group. A visualization of the proposed measure is presented in Figure 1.   
In this paper, we propose a nonparametric method that connects a value function with the 
final subgroups identified. The value function is defined using the abovementioned measure of 
subgroup identification which reflects the subgroup-treatment interaction. The goal is to identify 
the treatment performing subgroup and its complementary subgroup, treatment non-performing 
subgroup, so that the differential treatment effects weighted by the prevalence of subgroups, 
measured by the value function, will be maximized. Instead of estimating the outcome or 
treatment contrast or utilizing outcome weighting at the patient-specific level, the proposed 
method compares difference in RMST in subgroups constructed by subgroup membership scores 
of patients. The subgroup membership scores are the parameters to be searched so that the 
treatment-subgroup interaction will be maximized. Gradient tree boosting is proposed to search 
for the optimal subgroup membership scores. Different from a typical use of gradient tree 
boosting solving a supervised classification problem with individual loss function (e.g. the 
Gradient Boosting Tree-based approach proposed by Sugasawa and Noma14 uses negative log-
Cox partial likelihood), the proposed value function does not involve individual label to evaluate 
misclassification error for individual patients. Our value function is based on measuring 
differential treatment effect at subpopulation level which may reduce variability coming from 
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unpredictable sources of patient variability so that the overall prediction error could be reduced.  
Although individual loss function is not defined, the value function is differentiable with respect 
to individual subgroup membership score and the gradient of the value function can be used in 
gradient tree boosting.  
The remainder of the paper is organized as follows. In section 2, we present the proposed 
method. We conduct simulation studies to evaluate performance of the proposed method in 
section 3. In section 4, we apply the proposed method to a randomized AIDS clinical trial. We 
conclude the paper with a discussion in section 5. 
2 Materials and Methods 
Assume we have a two-armed randomized controlled trial in which treatment is equally assigned 
to n patients from a population of interest. We let 𝐴𝐴 = 0 or 1 be the binary treatment indicator 
for control and experimental treatment, respectively. Furthermore, denote 𝑇𝑇1, … ,𝑇𝑇𝑛𝑛 as the true 
survival times and 𝐶𝐶1, … ,𝐶𝐶𝑛𝑛 the censoring times for the n patients. We define the observed 
survival time and censoring indicator as 𝑋𝑋𝑖𝑖 = min(𝑇𝑇𝑖𝑖,𝐶𝐶𝑖𝑖), 𝛿𝛿𝑖𝑖 = 𝐼𝐼(𝑇𝑇𝑖𝑖 ≤ 𝐶𝐶𝑖𝑖), and further assume Z 
as a q-dimensional baseline patient characteristic vector. The observed data are then {𝑌𝑌𝑖𝑖 = (𝑋𝑋𝑖𝑖,𝛿𝛿𝑖𝑖),𝐴𝐴𝑖𝑖 ,𝒁𝒁𝑖𝑖} for 𝑖𝑖 = 1,2, … ,𝑛𝑛, which are assumed to be independently and identically 
distributed.  
2.1 Proposed Value Function 
We propose the below value function as a measure of the clinical interest associated with the 
subgroups to be identified. 
𝑉𝑉(𝜏𝜏) = 𝑃𝑃[𝜏𝜏(𝒁𝒁) = 1]{𝐸𝐸[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 1] − 𝐸𝐸[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 1]} 
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          −𝑃𝑃[𝜏𝜏(𝒁𝒁) = 0]{𝐸𝐸[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 0] − 𝐸𝐸[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 0]} (1) 
where 𝜏𝜏 is a rule to be estimated defining the subgroup membership according to Z, so that 
patients with 𝜏𝜏(𝒁𝒁) = 1 belong to the subgroup that experimental treatment leads to better clinical 
outcome (treatment performing subgroup), and patients with 𝜏𝜏(𝒁𝒁) = 0 belong to the subgroup 
that experimental treatment does not lead to better clinical outcome (treatment non-performing 
subgroup). The proposed value function can be viewed as a measure of differential experimental 
treatment effects across subgroups weighted by the subgroup prevalence. A visualization of the 
value function can be found in Figure 1.  
To estimate 𝑉𝑉(𝜏𝜏) one could first to estimate 𝐸𝐸[𝑌𝑌|𝐴𝐴, 𝜏𝜏(𝒁𝒁)]. For survival data, 𝐸𝐸[𝑌𝑌|𝐴𝐴, 𝜏𝜏(𝒁𝒁)] 
can be estimated using restricted mean survival time (RMST) estimate ∫ 𝑆𝑆(𝑡𝑡)𝑡𝑡∗0 𝑑𝑑𝑡𝑡,  39–41 where 
𝑆𝑆(𝑡𝑡) is the survival function estimate for the corresponding population and 𝑡𝑡∗ is a predefined 
cutoff time point for the RMST calculation. For example, 𝑡𝑡∗ can be set as the maximum observed 
follow-up time. For a given subgroup, 𝑆𝑆(𝑡𝑡) can be estimated by the Nelson–Aalen estimate. 42 
For example,  𝑆𝑆(𝑡𝑡) for experimental treatment arm (A=1) in treatment performing subgroup can 
be estimated as below, 
?̂?𝑆(𝑡𝑡,𝐴𝐴 = 1, 𝜏𝜏 = 1) = 𝑒𝑒−∑ ∑ 𝐼𝐼(𝜏𝜏𝑖𝑖=1)𝐼𝐼(𝑋𝑋𝑖𝑖=𝑡𝑡𝑘𝑘)𝐼𝐼(𝛿𝛿𝑖𝑖=1)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1∑ 𝐼𝐼(𝜏𝜏𝑖𝑖=1)𝐼𝐼(𝑋𝑋𝑖𝑖≥𝑡𝑡𝑘𝑘)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1𝑡𝑡𝑘𝑘≤𝑡𝑡  (2) 
where 𝐼𝐼(𝜏𝜏𝑖𝑖 = 1) is the indicator function determining whether the i-th patient belongs to the 
treatment performing subgroup or not. The problem remains is we do not have the observed data 
of subgroup membership beforehand. Here we define a subgroup membership score 𝑝𝑝(𝒁𝒁𝑖𝑖) for 
each patient which can be viewed as an estimate of 𝑃𝑃[𝜏𝜏(𝒁𝒁𝑖𝑖) = 1]: the probability of 
experimental treatment (A=1) is recommended to i-th patient given 𝒁𝒁𝒊𝒊. 1 − 𝑝𝑝(𝒁𝒁𝑖𝑖) then is an 
estimate of 𝑃𝑃[𝜏𝜏(𝒁𝒁𝑖𝑖) = 0]: the probability of control drug (A=0) is recommended to i-th patient 
9 
 
 
given 𝒁𝒁𝒊𝒊. If we replace 𝐼𝐼(𝜏𝜏𝑖𝑖 = 1) in (2) with 𝑝𝑝(𝒁𝒁𝑖𝑖) we can then estimate the survival function for 
experimental treatment arm in treatment performing subgroup as, 
?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,𝒑𝒑) = 𝑒𝑒−∑ ∑ 𝑝𝑝(𝒁𝒁𝑖𝑖)𝐼𝐼(𝑋𝑋𝑖𝑖=𝑡𝑡𝑘𝑘)𝐼𝐼(𝛿𝛿𝑖𝑖=1)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1∑ 𝑝𝑝(𝒁𝒁𝑖𝑖)𝐼𝐼(𝑋𝑋𝑖𝑖≥𝑡𝑡𝑘𝑘)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1𝑡𝑡𝑘𝑘≤𝑡𝑡  (3) 
where 𝒑𝒑 = [𝑝𝑝1(𝒁𝒁) ⋯ 𝑝𝑝𝑛𝑛(𝒁𝒁)]T.  Similarly, survival functions for the remaining three 
subgroups defined by the agreement or disagreement of A and 𝜏𝜏 can be estimated using the 
formulas below 
⎩
⎪⎪
⎨
⎪⎪
⎧
 
?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,𝒑𝒑) = 𝑒𝑒−∑ ∑ 𝑝𝑝(𝒁𝒁𝑖𝑖)𝐼𝐼(𝑋𝑋𝑖𝑖=𝑡𝑡𝑘𝑘)𝐼𝐼(𝛿𝛿𝑖𝑖=1)𝐼𝐼(𝐴𝐴𝑖𝑖=0)𝑛𝑛𝑖𝑖=1∑ 𝑝𝑝(𝒁𝒁𝑖𝑖)𝐼𝐼(𝑋𝑋𝑖𝑖≥𝑡𝑡𝑘𝑘)𝐼𝐼(𝐴𝐴𝑖𝑖=0)𝑛𝑛𝑖𝑖=1𝑡𝑡𝑘𝑘≤𝑡𝑡
?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,1 − 𝒑𝒑) = 𝑒𝑒−∑ ∑ [1−𝑝𝑝(𝒁𝒁𝑖𝑖)]𝐼𝐼(𝑋𝑋𝑖𝑖=𝑡𝑡𝑘𝑘)𝐼𝐼(𝛿𝛿𝑖𝑖=1)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1[1−𝑝𝑝(𝒁𝒁𝑖𝑖)]𝐼𝐼 ∑ 𝐼𝐼(𝑋𝑋𝑖𝑖≥𝑡𝑡𝑘𝑘)𝐼𝐼(𝐴𝐴𝑖𝑖=1)𝑛𝑛𝑖𝑖=1𝑡𝑡𝑘𝑘≤𝑡𝑡
?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,1 − 𝒑𝒑) = 𝑒𝑒−∑ ∑ [1−𝑝𝑝(𝒁𝒁𝑖𝑖)]𝐼𝐼(𝑋𝑋𝑖𝑖=𝑡𝑡𝑘𝑘)𝐼𝐼(𝛿𝛿𝑖𝑖=1)𝐼𝐼(𝐴𝐴𝑖𝑖=0)𝑛𝑛𝑖𝑖=1[1−𝑝𝑝(𝒁𝒁𝑖𝑖)]𝐼𝐼 ∑ 𝐼𝐼(𝑋𝑋𝑖𝑖≥𝑡𝑡𝑘𝑘)𝐼𝐼(𝐴𝐴𝑖𝑖=0)𝑛𝑛𝑖𝑖=1𝑡𝑡𝑘𝑘≤𝑡𝑡
 
where ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,𝒑𝒑) is the survival function estimate for control arm in treatment performing 
subgroup; ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,1 − 𝒑𝒑) is the survival function estimate for experimental treatment arm in 
treatment non-performing subgroup; ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,1 − 𝒑𝒑) is the survival function estimate for 
control arm in treatment non-performing subgroup. 𝐸𝐸[𝑌𝑌|𝐴𝐴, 𝜏𝜏(𝒁𝒁)] for the four subgroups can then 
be estimated as follows, 
⎩
⎪
⎪
⎪
⎨
⎪
⎪
⎪
⎧ 𝐸𝐸�[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 1] = � ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,𝒑𝒑)𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 
𝐸𝐸�[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 1] = � ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,𝒑𝒑)𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 
𝐸𝐸�[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 0] = � ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,1 − 𝒑𝒑)𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 
𝐸𝐸�[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 0] = � ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,1 − 𝒑𝒑)𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 
 
With the above estimates for 𝐸𝐸[𝑌𝑌|𝐴𝐴, 𝜏𝜏(𝒁𝒁)], we propose to estimate 𝑉𝑉(𝜏𝜏) as below, 
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𝑉𝑉� = ��𝑝𝑝𝑖𝑖𝑛𝑛
𝑖𝑖=1
�� �?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,𝒑𝒑) − ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,𝒑𝒑)�𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 − � (1 − 𝑝𝑝𝑖𝑖)𝑛𝑛
𝑖𝑖=1
�� �?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,1 − 𝒑𝒑) − ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,1 − 𝒑𝒑)�𝑡𝑡∗
0
𝑑𝑑𝑡𝑡 (4) 
The goal is to estimate the subgroup membership score 𝑝𝑝(𝒁𝒁𝑖𝑖) for patients by maximizing the 
value function estimator in (4). Once 𝑝𝑝(𝒁𝒁𝑖𝑖) are estimated, we can stratify the overall population 
to treatment performing subgroup with patients with 𝑝𝑝(𝒁𝒁𝑖𝑖) > 𝑐𝑐, and to treatment non-performing 
subgroup with patients with 𝑝𝑝(𝒁𝒁𝑖𝑖) ≤ 𝑐𝑐, where c is a cutoff, for example c can be 0.5.  
2.2 Comparison Between Proposed Value Function and ITR Value Function 
Note that under the setting of a two-armed 1:1 randomized controlled trial, (1) can be re-written 
as, 
𝑉𝑉(𝜏𝜏) = 𝐸𝐸 �𝑌𝑌𝐼𝐼�𝐴𝐴 = 𝜏𝜏(𝒁𝒁)�
𝑃𝑃(𝑨𝑨|𝒁𝒁) � − 𝐸𝐸 �𝑌𝑌𝐼𝐼�𝐴𝐴 ≠ 𝜏𝜏(𝒁𝒁)�𝑃𝑃(𝑨𝑨|𝒁𝒁) � (5) 
To see that we first show the first term in (5) can be re-written as, 
𝐸𝐸 �
𝑌𝑌𝐼𝐼�𝐴𝐴 = 𝜏𝜏(𝒁𝒁)�
𝑃𝑃(𝐴𝐴|𝒁𝒁) � = �𝑌𝑌𝐼𝐼[𝐴𝐴 = 𝜏𝜏(𝒁𝒁)]
𝑌𝑌𝒁𝒁𝐴𝐴
𝑃𝑃(𝑌𝑌|𝐴𝐴,𝒁𝒁)𝑃𝑃(𝒁𝒁) 
= �𝑌𝑌𝑃𝑃[𝜏𝜏 = 1]𝑃𝑃{𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 1} +
𝑌𝑌
�𝑌𝑌𝑃𝑃[𝜏𝜏 = 0]𝑃𝑃{𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 0}
𝑌𝑌
 
                = 𝑃𝑃[𝜏𝜏 = 1]𝐸𝐸[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 1] + 𝑃𝑃[𝜏𝜏 = 0]𝐸𝐸[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 0] (6) 
 Similarly, the second term in (5) can be re-written as, 
𝐸𝐸 �
𝑌𝑌𝐼𝐼�𝐴𝐴 ≠ 𝜏𝜏(𝒁𝒁)�
𝑃𝑃(𝐴𝐴|𝒁𝒁) � = 𝑃𝑃[𝜏𝜏 = 1]𝐸𝐸[𝑌𝑌|𝐴𝐴 = 0, 𝜏𝜏(𝒁𝒁) = 1] + 𝑃𝑃[𝜏𝜏 = 0]𝐸𝐸[𝑌𝑌|𝐴𝐴 = 1, 𝜏𝜏(𝒁𝒁) = 0] (7) 
Therefore, subtracting (7) from (6) one can get the proposed value function in (1). Note that the 
first term in (5) is the widely used value function proposed by Qian and Murphy23 under the ITR 
framework and is maximized when  
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𝜏𝜏(𝒁𝒁) = �1,𝐸𝐸(𝑌𝑌|𝐴𝐴 = 1,𝒁𝒁) > 𝐸𝐸(𝑌𝑌|𝐴𝐴 = 0,𝒁𝒁)0,𝐸𝐸(𝑌𝑌|𝐴𝐴 = 1,𝒁𝒁) ≤ 𝐸𝐸(𝑌𝑌|𝐴𝐴 = 0,𝒁𝒁) (8) 
Finding τ maximizing (6) is equivalent to finding τ minimizing (7) so the proposed value 
function in (1) will also be maximized when 𝜏𝜏 follows the equation (8). But different from 
comparing the predicted value of 𝐸𝐸(𝑌𝑌|𝐴𝐴 = 1,𝒁𝒁) versus 𝐸𝐸(𝑌𝑌|𝐴𝐴 = 0,𝒁𝒁) or directly maximizing 
the value function utilizing individual level outcome weighting, we propose to take apart the 
value function in (1) into expected outcome at subgroup level and directly maximize the value 
function comparing mean survival time among subpopulations defined by the agreement or 
disagreement of A and 𝜏𝜏. Instead of estimating treatment effect at individual level, we focus on 
treatment effect at subpopulation level to search for the optimizer for 𝜏𝜏. 
2.3 Estimation via Gradient Tree Boosting 
The gradient tree boosting is an ensemble method that constructs a predictive model by additive 
expansions of decision trees. 43 For the proposed method, we define 𝐹𝐹𝑖𝑖 as a logit function of 
𝑝𝑝(𝒁𝒁𝑖𝑖) for patient 𝑖𝑖 = 1, … ,𝑛𝑛. 
𝐹𝐹𝑖𝑖 = 𝑙𝑙𝑙𝑙𝑙𝑙 � 𝑝𝑝(𝒁𝒁𝑖𝑖)1 − 𝑝𝑝(𝒁𝒁𝑖𝑖)� (9) 
The final prediction 𝐹𝐹�𝑖𝑖 of 𝐹𝐹𝑖𝑖 follows an additive expansion of K base tree functions. 
𝐹𝐹�𝑖𝑖 = �𝑓𝑓𝑘𝑘(𝑌𝑌𝑖𝑖,𝐴𝐴𝑖𝑖 ,𝒁𝒁𝑖𝑖)𝐾𝐾
𝑘𝑘=1
 (10) 
where 𝑓𝑓𝑘𝑘 is the k-th base tree function and K is the number of trees. To learn the set of base tree 
functions, the following regularized objective function is minimized at each of the K iterations. 44 
𝑙𝑙𝑜𝑜𝑜𝑜(𝑘𝑘) = ℒ ��𝐹𝐹�1(𝑘𝑘−1) + 𝑓𝑓𝑘𝑘(𝑌𝑌1,𝐴𝐴1,𝒁𝒁1),⋯  ,𝐹𝐹�𝑛𝑛(𝑘𝑘−1) + 𝑓𝑓𝑘𝑘(𝑌𝑌𝑛𝑛,𝐴𝐴𝑛𝑛,𝒁𝒁𝑛𝑛)�T� + Ω (11) 
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where ℒ is a differentiable loss function we want to minimize, Ω is a penalty function that 
penalizes the complexity of the tree functions and 𝐹𝐹�𝑖𝑖
(𝑘𝑘−1) = ∑ 𝑓𝑓𝑗𝑗(𝑌𝑌𝑖𝑖,𝐴𝐴𝑖𝑖 ,𝒁𝒁𝑖𝑖)𝑘𝑘−1𝑗𝑗=1  is the prediction 
up to the (k-1)-th base tree function. We present the proposed value function estimator in (4), 
here we simply set the loss function ℒ = −𝑉𝑉� , the negative value function. We use the same 
penalty function as defined in xgboost. 44 Note that we do not define an individual loss function, 
so our loss function is not a direct summation of individual loss measuring counterfactual 
treatment effect at individual level. Instead, the loss function ℒ is a measure of differential 
treatment effect at subpopulation level. The loss function ℒ is differentiable with respect to 𝐹𝐹𝑖𝑖 
and the first-order approximation can be used to optimize the objective function. Specifically, at 
the k-th iteration, the first-order gradient of the loss function evaluated at 𝐹𝐹�𝑖𝑖
(𝑘𝑘−1), 𝑙𝑙𝑖𝑖𝑘𝑘 =(𝜕𝜕ℒ 𝜕𝜕𝐹𝐹𝑖𝑖⁄ )𝐹𝐹𝑖𝑖=𝐹𝐹�𝑖𝑖(𝑘𝑘−1),  can be used as the individual target label in the k-th tree to construct the 
prediction of 𝑓𝑓𝑘𝑘(𝑌𝑌𝑖𝑖,𝐴𝐴𝑖𝑖 ,𝒁𝒁𝑖𝑖). We provide the derivation of the first-order gradient in the 
supplementary materials. The goal is to optimize the final prediction for 𝐹𝐹𝑖𝑖 to minimize the 
objective function and we can classify patients based on their estimated subgroup membership 
score 𝑝𝑝(𝒁𝒁𝑖𝑖). The numerical optimization can be implemented with commonly used software 
such as “xgboost”. 44 
3 Simulation Studies 
We conduct simulation studies to evaluate the performance of the proposed method. We consider 
two settings: in the first setting we assume no prognostic variables with marginal effects are 
presented; in the second setting we assume that 4 prognostic variables are involved in the 
underlying survival model. Six scenarios of subgroup patterns are considered under both settings. 
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Specifically, we consider a two-armed 1:1 randomized clinical trial with a uniform enrollment of 
12 months followed by an 18 months study follow-up. We assume experimental treatment effects 
differ between two subgroups: treatment performing subgroup (Treatment > Control) and the 
treatment non-performing subgroup (Treatment ≤ Control). For each scenario we generate n=500 
independent survival time samples based on the following models, respectively:         Scenario 1: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+𝐴𝐴𝑆𝑆1+𝑍𝑍𝛽𝛽𝑧𝑧+𝜎𝜎0𝜀𝜀         Scenario 2: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+𝐴𝐴(𝑆𝑆1−𝑆𝑆2)+𝑍𝑍𝛽𝛽𝑧𝑧+𝜎𝜎0𝜀𝜀 
        Scenario 3: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+2𝐴𝐴�𝐼𝐼[−0.67≤𝑆𝑆1<0.67]�𝑒𝑒−𝑆𝑆12−0.4�+𝐼𝐼[𝑆𝑆1<−0.67 ⋃  𝑆𝑆1≥0.67]�𝑒𝑒−𝑆𝑆12−0.8�� +𝑍𝑍𝛽𝛽𝑧𝑧+𝜎𝜎0𝜀𝜀         Scenario 4: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+𝐴𝐴{2𝐼𝐼[(−1.07≤𝑆𝑆1<1.07)⋂(−1.07≤𝑆𝑆2<1.07)]−1}−(𝑍𝑍𝛽𝛽𝑧𝑧)2+𝜎𝜎0𝜀𝜀 
        Scenario 5: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+𝐴𝐴{2𝐼𝐼[(𝑆𝑆1≥0.67 )⋃(−0.67≤𝑆𝑆1<0 )]−1} −𝑍𝑍2𝛽𝛽𝑧𝑧+𝜎𝜎0𝜀𝜀         Scenario 6: 𝑇𝑇 = 𝑒𝑒𝛽𝛽0+𝐴𝐴{2𝐼𝐼[(𝑆𝑆1≥0 ⋂𝑆𝑆2≥−0.67 )⋃(𝑆𝑆1<0 ⋂𝑆𝑆2<−0.67 )]−1}−𝑍𝑍2𝛽𝛽𝑧𝑧+𝜎𝜎0𝜀𝜀 
where 𝑆𝑆1 and 𝑆𝑆2 are predictive variables involved in the determination of the above two 
subgroups and are generated along with the covariates 𝒁𝒁 = �𝑧𝑧1, … , 𝑧𝑧𝑞𝑞� using a mean zero 
multivariate normal distribution with a compound symmetric variance-covariance matrix 𝚺𝚺 =(1 − 𝜌𝜌)𝐈𝐈(𝑞𝑞+2) + 𝜌𝜌𝟏𝟏′𝟏𝟏, and 𝜀𝜀~𝑁𝑁(0,1). We let 𝑞𝑞 = 50, 𝜌𝜌 = 13 ,𝛽𝛽0 = √6,𝜎𝜎0 = 0.4,𝛽𝛽𝑍𝑍 =
�𝛽𝛽1⋯𝛽𝛽𝑞𝑞�
𝑇𝑇 = [0⋯ 0]𝑇𝑇 in setting 1 and 𝛽𝛽𝑍𝑍 = [0.4,0.4,0.4,0.4,0⋯0]𝑇𝑇 in setting 2. The treatment 
indicator A is generated as 0 or 1 with equal probability at random. Exponential censoring is 
simulated assuming a yearly dropout rate of 10%. Patients who do not have events are censored 
at the end of study. The censoring rate is around 30% in setting 1 and is around 35% in setting 2. 
The six scenarios are summarized in Figure 2. In scenario 1, greater value in 𝑆𝑆1 leads to greater 
experimental treatment benefit when 𝑆𝑆1 > 0, and experimental treatment turns harmful when 
𝑆𝑆1 < 0 and the magnitude of treatment harmfulness increases as value of 𝑆𝑆1 decreases. The two 
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subgroups can be perfectly separated by the linear boundary 𝑆𝑆1 = 0. In scenario 2, the linear 
boundary 𝑆𝑆1 = 𝑆𝑆2 can perfectly separate the two subgroups. The size of experimental treatment 
benefit or harmfulness changes along both the 𝑆𝑆1 axis and 𝑆𝑆2 axis. In scenario 3, the two 
subgroups can be separated by a nonlinear “U” shaped boundary. The magnitude of experimental 
treatment benefit increases when 𝑆𝑆1 gets closer to 0 and the magnitude of experimental treatment 
harmfulness increases when 𝑆𝑆1 gets farther away from 0.67 or -0.67. In scenario 4, Treatment > 
Control subgroup is “enclaved” by the Treatment ≤ Control subgroup. In scenario 5, the two 
subgroups can be separated by a “S” shaped nonlinear boundary. In scenario 6, the two 
subgroups are separated by two “L” shaped boundaries. In all scenarios, the Treatment > Control 
subgroup is simulated to be 50% of the total population.   
We compare the proposed method with four existing methods. Tian et al.20 proposed a 
regression-based method with modified covariates. Lasso-regularized cox regression is 
implemented using the R package “glmnet”. 45 Fivefold cross-validation is used to find the 
optimal 𝑙𝑙1 penalty parameter. This method is under the class of treatment effect modeling. Under 
the class of outcome modeling, Foster et al. proposed a 2-step approach with step-1 estimating 
the conditional outcome and step-2 fitting classification tree to identify subgroups. Under their 
framework, we first train a random survival forests model46 with treatment by covariate 
interaction terms included as input covariates. We then use predicted survival probabilities to 
compute the difference in RMST estimates between the two arms for each of the patient in 
training set. At step-2, we train a classification random forest model47 as the final prediction 
model with the dichotomized difference in RMST estimates obtained from step-1 as the target 
label. Both random survival forests and classification random forests are built with 1000 trees 
using the R package “randomForestSRC”. 46 We refer to this method as “VT”. In addition, 
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Sugasawa and Noma14 proposed to estimate the conditional outcome via gradient boosting trees 
and compute the individual treatment effect as the difference of survival probabilities between 
two arms for some fixed time t0. We choose t0 to be 20 months which is about the 75th percentile 
of the simulated censored survival times. Following what they did in their paper, we fit gradient 
boosting trees separately to the experimental treatment and control groups based on the partial 
likelihood function and include 𝑞𝑞 covariates and their interactions in the models. We set the 
maximum number of trees to 2000 and the optimal number of trees is selected via five-fold 
cross-validation. We classify a patient into treatment performing subgroup if the predicted 
individual treatment effect is greater than zero. We refer to this method as ‘SGBT’ and use R 
package ‘GBM’ to implement it. We also include an outcome weighted learning method, 
regularized outcome weighted subgroup identification (ROWSi), proposed by Xu et al.31 under 
the framework of outcome weighted learning. We use the 1-step version of their method without 
implementing the pre-screening group Lasso procedure as all variables are continuous in our 
simulation. R package “glmnet”45 is used to implement the method. We implement our proposed 
method using the R package xgboost44 which allows user defined loss function and evaluation 
function. We set the second order gradient to be 0.001 to implement first order gradient boosting. 
Note that since we set the second order gradient to be 0.001 we set the “min_child_weight”=0 to 
allow sufficient tree partitions. Five-fold cross-validation is used to find the optimal values for 
the step size shrinkage, maximum depth of a tree and number of trees. The other xgboost 
parameters are kept at default values. In our simulation, patients with ?̂?𝑝𝑖𝑖 > 0.5 are classified to 
treatment performing subgroup and patients with ?̂?𝑝𝑖𝑖 ≤ 0.5 are classified to treatment non-
performing subgroup. The R code for the customized loss function and evaluation function can 
be found in supplementary materials.  
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For all scenarios, we generate 1000 replicated datasets. In each replicated dataset we 
simulate data for 5500 patients, and we use 500 patients as the training set and use the remaining 
5000 as the validation set. In each simulated dataset, we compute the proposed value function 
estimate in (4) using validation set. Note the RMST is computed with time in month. Greater 
value function value indicates subgroups with greater magnitude of subgroup-treatment 
interaction effect are identified. In addition, since we know the true subgroup membership for 
each patient, we calculate the accuracy rate as the percentage of correctly predicted subgroup 
memberships in the validation set. Sensitivity and specificity are also calculated based on 
validation set. As a side product of the proposed method and VT, variable importance can be 
calculated from tree boosting and the classification random forests. We calculate the ranks of 𝑆𝑆1 
and 𝑆𝑆2 if available in the training set using the default “Gain” index in the xgboost and Gini 
index for the classification random forests. For Lasso and ROWSi, we order the variables by 
their shrunken coefficients and find the ranks of  𝑆𝑆1 and 𝑆𝑆2 if their coefficients are not shrunk to 
zero. If their coefficients are shrunk to zero, then we report their ranks as number of non-zero 
coefficients + median number of zero coefficients. For SGBT, we first compute the relative 
influence of each covariate under the models for the experimental treatment and control group, 
respectively. We then order all covariates by their absolute values of the difference in the relative 
influences between the two models and record the ranks for 𝑆𝑆1 and 𝑆𝑆2. 
The simulation results under setting 1 are summarized in Table 1 and simulation results 
under setting 2 are summarized in Table 2. In scenario 1 and scenario 2 when the subgroups are 
separable by simple linear boundaries, the modified covariate method provides the greatest value 
function estimates and highest prediction accuracies. The proposed method provides slightly less 
accuracy and value function estimate compared to SGBT in scenario 1 but outperforms SGBT in 
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scenario 2. The two gradient boosting trees-based methods both outperform the VT and ROWSi 
by a noticeable amount. When a “U” shaped boundary is presented (scenario 3), the proposed 
method becomes the winner by providing a value function estimate of 9.78 and a prediction 
accuracy of 0.97. The SGBT comes the second while the modified covariate method, VT and 
ROWSi’ value function estimates and prediction power drop sharply: VT provides a value 
function estimate of 2.99 and a prediction accuracy of 0.53, the modified covariate method and 
ROWSi provide a value function estimate close to 0 and a prediction accuracy of 0.5, suggesting 
no prediction power. Under scenario 4, the treatment performing subgroup is bounded in a 
rectangular “enclave”. The proposed method provides a value function estimate of 8.84 and a 
prediction accuracy of 0.87 while all the other methods provide limited prediction power. The 
SGBT, the method also utilizes the gradient boosting trees but is built upon the proportional 
hazard model, experiences a significant performance drop with a value function estimate of 4.79 
and a prediction accuracy of 0.62. Similarly, the proposed method outperforms the other methods 
in scenario 5 and 6 by a significant amount in the presence of more irregular boundary.  
The observations made from scenario 3-6 suggest that when the subgroup boundaries 
become more irregular, the performance of the regression based modified covariate method and 
ROWSi drop rapidly while the proposed method could still provide decent prediction power. The 
SGBT and VT methods also underperform the proposed method across most of the scenarios 
examined here. When several prognostic variables contribute to the variation in outcome (setting 
2), decline in performance is observed for all methods. Notably, the modified covariate method 
proposed by Tian et al.20 is not immune to the presence of prognostic effects even though the 
method nominally only estimates the interactions effects through modified covariates. Similar in 
setting 1, the proposed method outperforms others when boundaries become more irregular.   
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4 Real Data Analysis 
We apply the proposed method to an AIDS clinical trial data from ACTG17548 for the 
illustration purpose. The ACTG 175 is a randomized clinical trial to compare monotherapy with 
zidovudine (ZDV) or didanosine (DDI) with combination therapy with ZDV and DDI or ZDV 
and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T 
cell counts were between 200 and 500 per cubic millimeter. We subset the study population to 
treatment arms for ZDV + DDI and DDI monotherapy. The subset has 1083 patients with 522 
patients in ZDV + DDI arm and 561 patients in DDI monotherapy arm. As in32, we include 12 
covariates in addition to the treatment indicator. The 12 covariates include five continuous 
variables: age, weight, Karnofsky score, CD4 count at baseline and CD8 count at baseline, and 
seven binary covariates: hemophilia, homosexual activity, history of intravenous drug use, race, 
gender, antiretroviral history, and symptomatic status. The goal is to stratify the overall 
population into subgroups that patients may or may not benefit from ZDV + DDI relative to DDI 
alone.  
To reduce overfitting, we use cross-validation to estimate patients’ optimal treatment. 
Specifically, we partition the data into 5 roughly equal-sized sets based on original order of the 
observations in the dataset. At each iteration, we pick a different set as the validation set and 
perform the proposed method to the remaining 4 sets of the data to develop the subgroup 
membership prediction model. We then predict the subgroup memberships for patients in the 
validation set and stratify them into ZDV + DDI performing (ZDV+DDI > DDI) subgroup and 
ZDV + DDI non-performing (ZDV+DDI <= DDI) subgroup. A cutoff c of 0.5 is used. This way 
patients are not involved in the training process for the prediction model to estimate their 
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subgroup memberships. Among the 1083 patients, 800 patients are classified to the ZDV+DDI 
performing subgroup, 74% of overall population. In Figure 3, we plot the Kaplan–Meier survival 
curves for the two treatment arms in the overall population and two subgroups identified by the 
proposed method: ZDV+DDI > DDI and ZDV+DDI <= DDI.  From the plots, in the 
ZDV+DDI > DDI subgroup the curve for ZDV+DDI arm stays above the DDI arm curve and 
there is a greater gap between the two curves than it is in the overall population. In the 
ZDV+DDI <= DDI subgroup, there is not much difference between the two curves and the DDI 
arm has a slightly better survival than ZDV+DDI arm. We also estimate the value function using 
(4) based on the subgroups identified by the proposed method and the other methods, based on 
cross-validation. We conduct cross-validation 1000 times and compute the average and standard 
deviation of the value function estimates. The results are summarized in Table 3. The subgroups 
identified by the proposed method has the largest estimated value function, which is a measure of 
subgroup-treatment interaction effect and is the only one with a positive value meaning 
ZDV+DDI combination’s benefit over DDI monotherapy in the identified treatment performing 
subgroup is greater than it in the treatment non-performing subgroup. The negative value 
function estimated from other methods suggest there could be a mismatch between optimizing 
treatment effect at individual level and maximizing the differential treatment effect at the 
subgroup level. In contrast, by directly searching for maximized differential treatment effect at 
subgroup level, the recommended treatment should have the overall benefit over the alternative 
in both subpopulations identified by the proposed method. In other words, precision medicine 
should have a sensible population interpretation as well, and that motivates our value function.   
Difference in RMST and hazard ratio between two treatment arms across the two subgroups 
identified by the proposed method based on cross-validation are summarized in Table 4. Finally, 
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we fit the model to the overall sample and plot the Kaplan–Meier survival curves for the two 
identified subgroups in Figure S1. The variable importance from the tree boosting is summarized 
in the Figure S2 in supplementary materials. The weight, age and Karnofsky score are the top 3 
most important variables to determine the subgroup membership. The above findings suggest 
ZDV+DDI combination could be preferred to DDI monotherapy for most of the patients but 
there could be a subgroup of patients who may not benefit from the combination.  
5 Discussion 
Tree-based ensemble methods which enjoy flexible model structure have unique advantages in 
precision medicine. In this paper we propose a nonparametric method to search for subgroup 
membership scores by maximizing a value function that directly reflects the subgroup-treatment 
interaction effect. The simulation results suggest that the proposed method could outperform 
existing methods in some scenarios when subgroup boundaries become irregular. As an 
alternative value function, one could follow Qian and Murphy’s23 strategy and sets the value 
function as in (6) and estimate it as below, 
𝐸𝐸� �
𝑌𝑌𝐼𝐼�𝐴𝐴=𝜏𝜏(𝒁𝒁)�
𝑃𝑃(𝐴𝐴|𝒁𝒁) � = �(∑ 𝑝𝑝𝑖𝑖𝑛𝑛𝑖𝑖=1 )∫ ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 1,𝒑𝒑)𝑡𝑡∗0 𝑑𝑑𝑡𝑡 + [∑ (1 − 𝑝𝑝𝑖𝑖)𝑛𝑛𝑖𝑖=1 ]∫ ?̃?𝑆(𝑡𝑡,𝐴𝐴 = 0,1 − 𝒑𝒑)𝑡𝑡∗0 𝑑𝑑𝑡𝑡�  (12)  
We include additional two terms for 𝐸𝐸[𝑌𝑌|𝐴𝐴 ≠ 𝜏𝜏] in the proposed objective function so that the 
value function can be used as a measure of subgroup-treatment interaction effect. We compare 
the value function estimator in (12) to the value function estimator in (4) through simulation and 
the value function in (4) consistently provides slightly better prediction power and therefore is 
proposed. 
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The gradient tree boosting algorithm as applied in the proposed method enables the direct 
search for the “propensity” of treatment-recommending subgroup membership. The use of 
population-level gradient for each subject-specific subgroup membership score in the boosting 
algorithm has not been previously proposed in the personalized medicine literature based on our 
research. We believe this technique has further potential in a broader class of problems. 
The proposed method has limitations. It is primarily designed for a two-armed randomized 
clinical trial with censored survival data. For observational studies when prognostic variables 
could correlate with the treatment assignment, the signal captured by the proposed value function 
may not be due to heterogenous responses to treatments. Extension to multiple treatment setting 
could be made by modifying the value function to 𝑉𝑉� = ∑ �(∑ 𝑝𝑝𝑘𝑘𝑖𝑖𝑛𝑛𝑖𝑖=1 )∫ 𝑆𝑆(𝑡𝑡,𝐴𝐴 = 𝑘𝑘,𝒑𝒑𝑘𝑘)𝑡𝑡∗0 𝑑𝑑𝑡𝑡�𝐾𝐾𝑘𝑘=1  
for K treatment arms with ∑ 𝑝𝑝𝑘𝑘𝑖𝑖 = 1𝐾𝐾𝑘𝑘=1 .  Moreover, extension to continuous and binary outcome 
could be made by replacing RMST with alternative estimator, such as sample mean, for 
𝐸𝐸(𝑌𝑌|𝐴𝐴, 𝜏𝜏). The proposed method also suffers from the presence of prognostic variables. A value 
function that integrated from stratified value functions across prognostic variables defined 
subgroups could reduce the influence of prognostic effects. In addition, the estimated subgroup 
membership score is a continuous quantity used to determine subgroup membership with a cutoff 
c. In simulation study and real data application we use c=0.5 and it leads to decent subgroup 
identification results. But 0.5 may not be the optimal value and in practice we may be only 
confident to declare subgroup memberships to patients with scores well greater or less than 0.5.  
In practice, researchers often want to make statistical inference about the identified 
subgroups and associated differential treatment effect. Permutation test might be used for this 
purpose. For example, one could first optimize and estimate the value function based on 
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observed sample and then repeat randomly “shuffled” datasets a large number of times and at 
each time generate and save the maximized value function estimate. If the value function 
estimate based on observed data is greater than the 1-α quantile of the value function estimates 
from randomly permuted datasets, one could conclude that the identified differential treatment 
effect is indeed present. These extensions will be the subjects of our future research. Lastly the 
proposed method is not immune to common problems in statistical learning such as false positive 
and overfitting and it may not be easy to interpret the subgroups identified as the prediction 
model could be based on multiple trees. The proposed method should be used as an exploratory 
tool and it is crucial to have an independent validation set to verify the findings. 
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Figure 1. Visualization of the value function as a measure of the differential treatment effects 
across subgroups identified. The value function is a weighted integration of difference in RMST 
estimates, a measure of gaps between treatment arm survival curve and control arm survival 
curve, across the two identified subgroups weighted by subgroup prevalence.  
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Figure 2. Six scenarios of underlying subgroup patterns. 
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Table 1 Simulation results when no prognostic factors are presented (setting 1) for value 
function estimates, classification accuracy, sensitivity, specificity based on validation set, and 
predictive variable ranking(s) based on training set  
 Method 
 Proposed 
Method 
SGBT Modified 
Covariate 
Virtual Twins ROWSi 
Scenario 1 
𝑉𝑉�(𝜏𝜏) (s.d.) 7.19 (0.35) 7.46 (0.31) 7.54 (0.26) 4.45 (1.11) 6.54 (1.06) 
Accuracy (s.d.) 0.93 (0.03) 0.94 (0.04) 0.96 (0.03) 0.67 (0.08) 0.86 (0.07) 
Sensitivity (s.d.) 0.94 (0.05) 0.98 (0.04) 0.96 (0.04) 0.99 (0.02) 0.78 (0.14) 
Specificity (s.d.) 0.93 (0.06) 0.89 (0.09) 0.97 (0.03) 0.36 (0.17) 0.94 (0.08) 
Rank (S1, S2) (1.00, NA) (1.00, NA) (1.00, NA) (1.00, NA) (1.11, NA) 
Scenario 2 
𝑉𝑉�(𝜏𝜏) (s.d.) 6.73 (0.57) 5.98 (0.99) 8.16 (0.26) 1.51 (1.26) 6.43 (1.42) 
Accuracy (s.d.) 0.82 (0.04) 0.75 (0.07) 0.95 (0.03) 0.52 (0.03) 0.82 (0.07) 
Sensitivity (s.d.) 0.86 (0.06) 1.00 (0.01) 0.95 (0.03) 0.99 (0.02) 0.74 (0.14) 
Specificity (s.d.) 0.77 (0.08) 0.49 (0.14) 0.95 (0.03) 0.04 (0.07) 0.90 (0.12) 
Rank (S1, S2) (1.50, 1.50) (1.50, 1.5) (1.48, 1.52) (1.81, 1.58) (2.13, 2.01) 
Scenario 3 
𝑉𝑉�(𝜏𝜏) (s.d.) 9.78 (0.34) 9.08 (0.66) 0.80 (1.16) 2.99 (0.82) 0.14 (0.90) 
Accuracy (s.d.) 0.97 (0.02) 0.91 (0.04) 0.50 (0.01) 0.53 (0.02) 0.50 (0.01) 
Sensitivity (s.d.) 0.99 (0.01) 1.00 (0.00) 0.92 (0.22) 1.00 (0.00) 0.62 (0.41) 
Specificity (s.d.) 0.95 (0.04) 0.82 (0.09) 0.08 (0.22) 0.07 (0.05) 0.38 (0.40) 
Rank (S1, S2) (1.00, NA) (1.00, NA) (27.33, NA) (1.11, NA) (26.11, NA) 
Scenario 4 
𝑉𝑉�(𝜏𝜏) (s.d.) 8.84 (0.44) 4.79 (0.58) 1.14 (1.56) 3.42 (1.19) 0.35 (1.05) 
Accuracy (s.d.) 0.87 (0.02) 0.62 (0.03) 0.52 (0.01) 0.54 (0.01) 0.51 (0.02) 
Sensitivity (s.d.) 0.99 (0.02) 1.00 (0.00) 0.97 (0.07) 1.00 (0.00) 0.77 (0.32) 
Specificity (s.d.) 0.75 (0.04) 0.20 (0.06) 0.03 (0.08) 0.04 (0.03) 0.23 (0.32) 
Rank (S1, S2) (1.66, NA) (1.62, NA) (28.25, NA) (7.54, NA) (26.84, NA) 
Scenario 5 
𝑉𝑉�(𝜏𝜏) (s.d.) 9.74 (1.22) 1.73 (2.70) 4.24 (1.33) 2.83 (1.39) 2.10 (1.76) 
Accuracy (s.d.) 0.94 (0.08) 0.55 (0.10) 0.64 (0.05) 0.53 (0.03) 0.58 (0.06) 
Sensitivity (s.d.) 0.98 (0.02) 1.00 (0.00) 0.84 (0.12) 1.00 (0.00) 0.70 (0.26) 
Specificity (s.d.) 0.91 (0.14) 0.11 (0.21) 0.45 (0.10) 0.05 (0.05) 0.46 (0.30) 
Rank (S1, S2) (1.00, NA) (1.00, NA) (1.17, NA) (1.33, NA) (9.83, NA) 
Scenario 6 
𝑉𝑉�(𝜏𝜏) (s.d.) 9.56 (1.69) 2.20 (3.29) 3.53 (2.11) 0.04 (0.46) 1.90 (2.03) 
Accuracy (s.d.) 0.90 (0.10) 0.63 (0.09) 0.59 (0.02) 0.58 (0.01) 0.59 (0.04) 
Sensitivity (s.d.) 0.98 (0.03) 1.00 (0.00) 0.96 (0.04) 1.00 (0.00) 0.89 (0.17) 
Specificity (s.d.) 0.80 (0.22) 0.10 (0.21) 0.07 (0.09) 0.00 (0.00) 0.16 (0.23) 
Rank (S1, S2) (2.65, 2.20) (1.92, 1.09) (2.30, 22.77) (6.09, 6.03) (16.87, 26.69) 
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Table 2 Simulation results when prognostic factors are presented (setting 2) for value function 
estimates, classification accuracy, sensitivity, specificity based on validation set, and predictive 
variable ranking(s) based on training set  
 Method 
 Proposed 
Method 
SGBT Modified 
Covariate 
Virtual Twins ROWSi 
Scenario 1 
𝑉𝑉�(𝜏𝜏) (s.d.) 3.24 (0.78) 3.72 (0.41) 3.76 (0.96) 0.84 (0.98) 1.57 (1.57) 
Accuracy (s.d.) 0.79 (0.08) 0.84 (0.05) 0.86 (0.12) 0.56 (0.10) 0.65 (0.14) 
Sensitivity (s.d.) 0.79 (0.13) 0.93 (0.08) 0.84 (0.18) 0.92 (0.15) 0.48 (0.35) 
Specificity (s.d.) 0.78 (0.14) 0.74 (0.11) 0.88 (0.12) 0.20 (0.25) 0.82 (0.30) 
Rank (S1, S2) (s.d.) (1.23, NA) (1.00, NA) (1.87, NA) (8.29, NA) (10.08, NA) 
Scenario 2 
𝑉𝑉�(𝜏𝜏) (s.d.) 4.00 (0.82) 3.85 (0.51) 5.81 (0.48) 1.15 (1.03) 3.39 (1.92) 
Accuracy (s.d.) 0.71 (0.05) 0.67 (0.03) 0.86 (0.06) 0.53 (0.04) 0.68 (0.12) 
Sensitivity (s.d.) 0.72 (0.11) 0.85 (0.07) 0.86 (0.06) 0.85 (0.18) 0.62 (0.26) 
Specificity (s.d.) 0.70 (0.12) 0.49 (0.10) 0.86 (0.07) 0.21 (0.22) 0.75 (0.26) 
Rank (S1, S2) (4.16, 2.31) (1.00, 5.1) (1.79, 1.34) (15.33, 20.63) (9.23, 7.51) 
Scenario 3 
𝑉𝑉�(𝜏𝜏) (s.d.) 6.28 (1.06) 5.46 (0.78) 0.99 (0.82) 1.51 (1.08) 0.38 (0.70) 
Accuracy (s.d.) 0.89 (0.08) 0.82 (0.04) 0.51 (0.01) 0.55 (0.05) 0.50 (0.01) 
Sensitivity (s.d.) 0.93 (0.10) 0.94 (0.06) 0.41 (0.26) 0.91 (0.13) 0.51 (0.41) 
Specificity (s.d.) 0.85 (0.11) 0.69 (0.10) 0.61 (0.25) 0.19 (0.18) 0.49 (0.40) 
Rank (S1, S2) (1.10, NA) (1.00, NA) (24.17, NA) (8.69, NA) (26.15, NA) 
Scenario 4 
𝑉𝑉�(𝜏𝜏) (s.d.) 5.17 (0.62) 1.40 (1.66) 1.17 (1.39) 2.93 (1.02) 0.69 (1.16) 
Accuracy (s.d.) 0.81 (0.05) 0.53 (0.01) 0.52 (0.01) 0.54 (0.01) 0.52 (0.01) 
Sensitivity (s.d.) 0.97 (0.05) 1.00 (0.00) 0.92 (0.18) 1.00 (0.00) 0.95 (0.12) 
Specificity (s.d.) 0.64 (0.09) 0.02 (0.03) 0.09 (0.18) 0.04 (0.02) 0.06 (0.13) 
Rank (S1, S2) (2.57, 2.88) (1.84, 1.44) (28.11, 28.07) (12.49, 13.05) (26.72, 26.92) 
Scenario 5 
𝑉𝑉�(𝜏𝜏) (s.d.) 2.80 (0.56) 0.92 (1.06) 1.31 (0.84) 1.06 (0.94) 0.99 (0.95) 
Accuracy (s.d.) 0.74 (0.09) 0.52 (0.03) 0.60 (0.06) 0.51 (0.02) 0.55 (0.05) 
Sensitivity (s.d.) 0.91 (0.06) 1.00 (0.00) 0.75 (0.22) 1.00 (0.02) 0.94 (0.11) 
Specificity (s.d.) 0.57 (0.18) 0.04 (0.06) 0.45 (0.20) 0.02 (0.03) 0.15 (0.18) 
Rank (S1, S2) (1.18, NA) (1.00, NA) (4.26, NA) (5.16, NA) (12.67, NA) 
Scenario 6 
𝑉𝑉�(𝜏𝜏) (s.d.) 2.71 (0.93) 0.18 (0.63) 1.72 (0.81) 0.49 (0.94) 0.86 (1.02) 
Accuracy (s.d.) 0.71 (0.15) 0.58 (0.01) 0.60 (0.04) 0.58 (0.01) 0.59 (0.02) 
Sensitivity (s.d.) 0.90 (0.07) 1.00 (0.00) 0.87 (0.14) 1.00 (0.01) 0.95 (0.08) 
Specificity (s.d.) 0.44 (0.32) 0.01 (0.02) 0.23 (0.22) 0.01 (0.01) 0.08 (0.13) 
Rank (S1, S2) (10.65, 11.99) (1.67, 4.85) (5.38, 26.57) (11.21, 16.62) (15.67, 26.71) 
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Figure 3. The Kaplan–Meier survival curves in the overall population and subgroups identified 
by the proposed method using cross-validation for ACTG175. Left plot: Overall population. 
Middle plot: subgroup identified to be not benefited from ZDV+DDI compared to DDI 
monotherapy. Right plot: subgroup identified to be benefited from ZDV+DDI compared to DDI 
monotherapy. 
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Table 3 Summary of differential treatment effect across subgroups identified by different 
methods based on 1000 times randomly repeated cross-validation for ACTG175. RMST 
estimates are based on time in month 
 Differential Treatment effect between Subgroups 
Proposed 
Method 
SGBT Modified 
Covariate 
VT ROSWi 
𝑉𝑉�(𝜏𝜏) (s.d.) 0.60 (0.47) -0.01 (0.52) -0.64 (0.46) -0.17 (0.43) -0.44 (0.46) 
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Table 4 Summary of restricted mean survival time (RMST) difference and hazard ratio between 
two treatment arms within the subgroups identified by the proposed method using cross-
validation for ACTG175 
Population 
Difference in RMST (Month) 
(95% CI) 
Hazard Ratio 
(95% CI) 
Overall 0.85 (-0.28, 1.99) 0.84 (0.65, 1.09) 
ZDV+DDI>DDI 1.25 (-0.07, 2.56) 0.79 (0.59, 1.07) 
ZDV+DDI<=DDI -0.28 (-2.39, 1.83) 0.98 (0.59, 1.65) 
 
